Chemoinformaics analysis of ETHYL N-(O-ANISYL)FORMIMIDATE
| Molecular Weight | 179.219 | nRot | 4 |
| Heavy Atom Molecular Weight | 166.115 | nRig | 7 |
| Exact Molecular Weight | 179.095 | nRing | 1 |
| Solubility: LogS | -1.038 | nHRing | 0 |
| Solubility: LogP | 2.452 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 26 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 13 | No. of Aromatic Carbocycles | 1 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 13 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 6 |
| nHA | 3 | APOL | 28.0723 |
| nHD | 0 | BPOL | 17.6537 |
| QED | 0.525 |
| Synth | 2.404 |
| Natural Product Likeliness | -0.689 |
| NR-PPAR-gamma | 0.002 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.006 |
| HIA | 0.003 |
| CACO-2 | -4.625 |
| MDCK | 0.0000284 |
| BBB | 0.266 |
| PPB | 0.174527 |
| VDSS | 4.343 |
| FU | 0.63003 |
| CYP1A2-inh | 0.983 |
| CYP1A2-sub | 0.929 |
| CYP2c19-inh | 0.531 |
| CYP2c19-sub | 0.897 |
| CYP2c9-inh | 0.076 |
| CYP2c9-sub | 0.792 |
| CYP2d6-inh | 0.707 |
| CYP2d6-sub | 0.914 |
| CYP3a4-inh | 0.509 |
| CYP3a4-sub | 0.659 |
| CL | 7.192 |
| T12 | 0.589 |
| hERG | 0.01 |
| Ames | 0.97 |
| ROA | 0.041 |
| SkinSen | 0.194 |
| Carcinogencity | 0.971 |
| EI | 0.873 |
| Respiratory | 0.061 |
| NR-Aromatase | 0.018 |
| Antiviral | No |
| Prediction | 0.867821 |